Books by Subject
- 5-HT2C receptors in the pathophysiology of CNS disease — Developing drug products in an aging society : from concept to prescribing (130)
- Development of antibody-based therapeutics : translational considerations — Leading pharmaceutical innovation : trends and drivers for growth in the pharmaceutical industry. 2nd ed. (130)
- Lippincott's Illustrated reviews. Pharmacology. 4th ed. — Pharmacology-- PreTest self-assessment and review. 13th ed. (130)
- Pharmacology : PreTest self-assessment and review. 12th ed. — WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems (128)
- 2007[edited by] Marshal Shlafer.General principles -- The peripheral nervous systems: autonomic and somatic -- The central nervous system -- The cardiovascular system -- The renal system and diuretics -- The respiratory system: asthma and COPD -- Local control substances: autacoids and drugs for inflammatory processes -- The gastrointestinal system and nutrition -- The endocrine system, uterine stimulants, and relaxants -- Anti-infectives -- Cancer chemotherapy and immunosuppressants -- Toxicology.
- 2009 ScienceDirectedited by Miles Hacker, William Messer, Kenneth Bachmann.
- Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs : a comprehensive review on their mode of action, treatment of abuse and intoxication2009 SpringerEnno Freye ; in collaboration with Joseph V. Levy.
- 2010 SpringerMark E. Tomlin (ed.).Pharmacology -- Pharmacokinetic Principles -- Introduction to Specialist Therapeutics.
- 2013 ScienceDirect2013 ClinicalKey[edited by] Hugh C. Hemmings, Jr., Talmage D. Egan."Better understand the complexities of pharmacology and physiology relevant to your practice with the brand-new medical reference book, Anesthetic Pharmacology and Physiology. Drs. Hugh Hemmings and Talmage Egan provide the clinical insights you need to effectively administer anesthesia, ensuring patient safety and the most optimal outcomes. Access comprehensive, continually updated research on the physiology of organ systems and clinical topics in the pharmacology of anesthetic drugs. Quickly and easily reference the information you need through user-friendly tables, figures, and algorithms, all presented in lavish full color throughout. Understand the molecular mechanism of drug actions and identify key drug interactions that may complicate anesthesia with dedicated sections on these key areas"--Provided by publisher.
- 2009 ClinicalKey[edited by] Scott A. Waldman, Andre Terzic.Everything you need to know about all of today's drugs in a coherent, easy-to-use format - from the underlying science through innovation, translation, regulation, and clinical implementation. This multimedia resource fills a critical need for a more clinically focused, user-friendly pharmacology reference. Evidence-based therapeutic guidelines facilitate decision making; and coverage of pharmacogenetics and pharmacogenomics, regenerative pharmacology, stem cell therapies, and the emerging field of individualized medicine keeps you at the forefront of the latest developments.
- 2009 Kargervolume editor, Arnd Gandorfer.
- 2009 ClinicalKeyM. M. Dale, D. G. Haylett.The double page spreads in this book each cover a discrete topic and broadly correspond to the chapters of the main textbook 'Pharmacology' by Rang et al. Each spread includes at least one summary diagram and a small amount of text plus a 'clinical use' box.
- 2014 CambridgeT.E. Peck, Consultant Anaesthetist, Royal Hampshire County Hospital, Winchester ; Honorary Consultant, University Hospital Southampton, UK, S.A. Hill, Consultant Neuroanaesthetist, University Hospital Southampton, UK.Drug passage across the cell membrane -- Absorption, distribution, metabolism, and excretion -- Drug action -- Drug interaction -- Isomerism -- Pharmacokinetic modelling -- Applied pharmacokinetic models -- Medicinal chemistry -- General anaesthetic agents -- Analgesics -- Local anaesthetics -- Muscle relaxants and reversal agents -- Sympathomimetics -- Adrenoceptor antagonists -- Anti-arrhythmics -- Vasodilators -- Antihypertensives -- Central nervous system -- Antiemetics and related drugs -- Drugs acting on the gut -- Intravenous fluids and minerals -- Diuretics -- Antimicrobials -- Drugs affecting coagulation -- Drugs used in diabetes -- Corticosteroids and other hormone preparations.
- 2012 ScienceDirectTerry P. Kenakin.Chapter 1. Pharmacology: The Chemical Control of Physiology -- Chapter 2. Drug Affinity and Efficacy -- Chapter 3. Predicting Agonist Effect -- Chapter 4. Drug Antagonism: Orthosteric Drug Effects -- Chapter 5. Allosteric Drug Effects -- Chapter 6. Enzymes as Drug Targets -- Chapter 7. Pharmacokinetics I: Permeation and Metabolism -- Chapter 8. Pharmacokinetics II: Distribution and Multiple Dosing -- Chapter 9. In Vivo Pharmacology -- Chapter 10. Safety Pharmacology -- Chapter 11. Answers to Chapter Questions -- Chapter 12. Derivations and Proofs.
- 2012 SpringerVartika Jain, Surendra K. Verma."This work is the first monograph devoted solely to Bombax ceiba, popularly known as the Red Silk Cotton Tree. Consisting of seven chapters, it covers all relevant aspects of this plant, from its historical and spiritual importance, to its botanical characterization, pharmacognostical details and ethnobiological uses, to its scientific validation in various animal and human studies. Each part of the tree is of medicinal value and possesses many novel chemical constituents such as shamimicin, bombasin, bombamalone, bombamaloside etc. along with other bioactive secondary metabolites. The book presents the chemical structures of the most important constituents and highlights various pharmacological activities, predominantly antioxidant, anti-inflammatory, anti-mutagenic, hypoglycemic, hypotensive, hepatoprotective and fibrinolytic, which may prove to be a source for the development of a novel phyto-pharmaceutical agent to treat diabetes, heart disease and cancer. In addition, separate chapters deal with the commercial and ecological significance of B. ceiba, as well as a case study on its conservation. Numerous color illustrations are included to identify the plant and to justify its nickname, the “Little Bird's Cafeteria”."--Publisher's website.
- 2015 SpringerAlan Cowan, Gil Yosipovitch, editors.
- 2008 SpringerThomas C. Südhof, Klaus Starke, editors ; contributors, S. Boehm ... [et al.].
- 2009 ScienceDirectTerry P. Kenakin.What is pharmacology? -- How different tissues process drug response -- Drug-receptor theory -- Pharmacological assay formats : binding -- Agonists : the measurement of affinity and efficacy in functional assays -- Orthosteric drug antagonism -- Allosteric drug antagonism -- The process of drug discovery -- Pharmacokinetics -- Target- and system-based strategies for drug discovery -- "Hit" to drug : lead optimization -- Statistics and experimental design -- Selected pharmacological methods -- Exercises in pharmacodynamics and pharmacokinetics.
- 2007editor, Anand Ramachandran.
- 2007Gary C. Rosenfeld, David S. Loose ; with special contributions by Medina Kushen, Todd A. Swanson.
- 2008Todd A. Swanson, Sandra I. Kim, Medina C. Kushen.
- 2013 ClinicalKeyGeorge M. Brenner, Craig W. Stevens.Pharmacology, 4th Edition helps you master the "must-know" concepts in this subject and how they apply to everyday clinical problem solving and decision making. This concise yet comprehensive text clearly explains and illustrates challenging concepts and helps you retain the material - from course exams and the USMLE Step 1 right through to clinical practice. Quickly reference essential information thanks to abundant tables throughout, and drug classification boxes at the beginning of each chapter. See how pharmacology applies to practice with real-world case studies. Prepare for exams with self-assessment questions at the end of each chapter. Understand complex concepts visually with the aid of superb full-color illustrations. Access the complete contents online at www.studentconsult.com, along with an additional glossary, chapter-by-chapter summaries and case studies, a full list of featured drugs, 150 USMLE-style questions, animations, and more.
- 2011[editors-in-chief, Andrew W. Browne, Margaret A. Stefater, Sagar B. Dugani, Janine R. Hutson, Gordon G. McSheffrey].Adverse drug reaction icons -- Pharmacology basics -- Antimicrobial drugs -- Autonomic drugs -- Cancer chemotherapeutics -- Cardiovascular drugs -- Central nervous system drugs -- Endocrine drugs -- Gastrointestinal drugs -- Hematological drugs -- Immune response modifiers -- Renal and urological drugs -- Respiratory drugs -- Appendix A. Tricks for remembering drug names.
- 2013 SpringerLuisa Rocha, Esper A. Cavalheiro, editors.Although more than 10 new antiepileptic drugs have been developed in the past decade, epilepsy remains resistant to drug therapy in about one-third of patients, many of whom struggle with the disease their entire lives. Managing these patients is a challenge and requires a structured multidisciplinary approach. The book includes chapters on all issues related to pharmacoresistance in epilepsy, and describes recent developments in the pathogenesis and treatment of this disorder. It addresses abnormalities in inhibitory mechanisms, epilepsy-related changes to the immune system, development of pharmacoresistance caused by chronic exposure to antiepileptic drugs, and novel therapeutic strategies for preventing or slowing down the progression of the disease. Clinicians and basic scientists alike will find up-to-date information on the development of pharmacoresistance, as well as reviews of mechanisms associated with epilepsy that may help them consider novel strategies for preventing the development of pharmacoresistance in the first place. The book also features information on new therapeutic strategies for control of epilepsy, such as transcutaneous electrical stimulation and virtual screening of new antiepileptic drugs. Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies is useful to anyone working in the field, whether they're studying epilepsy in the lab or treating it in a doctor's office.
- 2015 SpringerArturo Evangelista, Christoph A. Nienaber, editors.This book is driven by the considerable progress made by novel imaging techniques in understanding the pathophysiology and evolution of aortic disease and its diagnosis. Despite the lack of symptoms in stable conditions, most aortic diseases have a high morbidity and mortality. New therapeutic strategies such as endovascular treatment and surgical techniques have appeared to improve conventional surgery in advanced phases of the disease, but until recently, medical treatment has focused on the control of cardiovascular risk factors using beta-blockers to reduce aortic wall stress by reducing blood pressure and heart rate. Pharmacotherapy in Aortic Disease updates the reader on the new medical treatment that are changing the natural history of these diseases. Leading experts have created a critical in-depth, yet concise, analysis of the available medical treatments for different aortic disease entities. Both basic research studies and clinical trials discussed in this book serve as a base for improving therapeutic management, delaying the need for surgery, and prolonging survival in these patients.
- 2013 SpringerMarc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch, editors.Definition and classification of pulmonary hypertension / Marc Humbert, David Montani, Oleg V. Evgenov, and Gérald Simonneau -- Pulmonary hypertension: pathophysiology and signaling pathways / Bradley A. Maron and Joseph Loscalzo -- Pulmonary hypertension: pathology / Peter Dorfmüller -- Pulmonary hypertension: biomarkers / Christopher J. Rhodes, John Wharton, and Martin R. Wilkins -- Rodent models of group 1 pulmonary hypertension / John J. Ryan, Glenn Marsboom, and Stephen L. Archer -- General supportive care / Ioana R. Preston -- Calcium-channel blockers in pulmonary arterial hypertension / Marie-Camille Chaumais, Elise Artaud Macari, and Olivier Sitbon -- Prostacyclins / Horst Olschewski -- Endothelin Receptor Antagonists / Martine Clozel, Alessandro Maresta, and Marc Humbert -- Phosphodiesterase-5 inhibitors / Barbara A. Cockrill and Aaron B. Waxman -- Inhaled nitric oxide for the treatment of pulmonary arterial hypertension / Steven H. Abman -- Soluble guanylate cyclase stimulators in pulmonary hypertension / Johannes-Peter Stasch and Oleg V. Evgenov -- Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction / Michael G. Risbano and Mark T. Gladwin -- Rho-kinase inhibitors / Yoshihiro Fukumoto and Hiroaki Shimokawa -- Serotonin transporter and serotonin receptors / Serge Adnot, Amal Houssaini, Shariq Abid, Elisabeth Marcos, and Valérie Amsellem -- Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension / Eva Berghausen, Henrik ten Freyhaus, and Stephan Rosenkranz -- Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension / Ly Tu and Christophe Guignabert -- Anti-inflammatory and immunosuppressive agents in PAH / Jolyane Meloche, Sébastien Renard, Steeve Provencher, and Sébastien Bonnet -- Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application / Reshma S. Baliga, Raymond J. MacAllister, and Adrian J. Hobbs -- Pulmonary hypertension: novel pathways and emerging therapies inhibitors of cGMP and cAMP metabolism / Yassine Sassi and Jean-Sébastien Hulot -- Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers) / Geoffrey Watson, Eduardo Oliver, Lan Zhao, and Martin R. Wilkins -- Pulmonary hypertension: current management and future directions / Lewis J. Rubin.
- 2007 WHO"There is considerable experience in the developed world with the use of antiretroviral medicines (ARVs). They are associated with significant safety concerns including serious adverse reactions to medicines (ADRs), with both short- and long-term effects. The outcome of these long-term adverse effects is unknown ... The monitoring of ARVs in these populations is therefore of paramount importance, and methods of monitoring are the subject of this article. This document should be considered in conjunction with a detailed assessment of the WHO publication, The safety of medicines in public health programmes: pharmacovigilance an essential tool"--Page 1.
- Pharmacovigilance guidance for countries participating in AMFm Phase 1 : WHO-MMV joint technical consultation on active pharmacovigilance monitoring with a special focus on AMFm : Geneva, 4-6 April 2009 International Center, Cointrin.2009 WHO
- 2012 WileyJustina Orleans-Lindsay.Pharmacovigilance medical writing : an overview across the drug development process -- Pharmacovigilance medical writing for clinical trials -- Pharmacovigilance medical writing for CTD submissions -- Pharmacovigilance medical writing in risk evaluation & management -- Pharmacovigilance medical writing for marketed products -- The Ad-Hoc safety review & response to questions document -- The rest of the world.
- 2013 Springer Protocolsedited by José Luis Millán.Chemical probe development versus drug development / Michael R. Jackson -- Phosphatase high-throughput screening assay design and selection / Eduard A. Sergienko -- Multisystemic functions of alkaline phosphatases / René Buchet, José Luis Millán, and David Magne -- Robotic implementation of assays : tissue-nonspecific alkaline phosphatase (TNAP) case study / Thomas D.Y. Chung -- Inhibitors of tissue-nonspecific alkaline phosphatase (TNAP) : from hits to leads / Peter Teriete, Anthony B. Pinkerton, and Nicholas D.P. Cosford -- Method for direct assessment of tissue-nonspecific alkaline phosphatase (TNAP) inhibitors in blood samples / Eduard A. Sergienko, Qing Sun, and Chen-Ting Ma -- Isolation and characteristics of matrix vesicles / René Buchet ... [et al.] -- Use of tissue-nonspecific alkaline phosphatase (TNAP) and PHOSPHO1 inhibitors to affect mineralization by cultured cells / Tina Kiffer-Moreira and Sonoko Narisawa -- Modulators of intestinal alkaline phosphatase / Ekaterina V. Bobkova, Tina Kiffer-Moreira, and Eduard A. Sergienko -- New activity assays for ENPP1 with physiological substrates ATP and ADP / Chen-Ting Ma and Eduard A. Sergienko -- Structure of acid phosphatases / César L. Araujo and Pirkko T. Vihko -- Purification of prostatic acid phosphatase (PAP) for structural and functional studies / Annakaisa M. Herrala, Ileana B. Quintero, and Pirkko T. Vihko -- Protein tyrosine phosphatases : structure, function, and implication in human disease / Lutz Tautz, David A. Critton, and Stefan Grotegut -- High-throughput screening for protein tyrosine phosphatase activity modulators / Lutz Tautz and Eduard A. Sergienko -- Evaluating effects of tyrosine phosphatase inhibitors on T cell receptor signaling / Souad Rahmouni ... [e tal.] -- Interactor-guided dephosphorylation by protein phosphatase-1 / Shannah Boens,... [et al.] -- Structure, regulation, and pharmacological modulation of PP2A phosphatases / Caroline Lambrecht ... [et al.].
- 2011 SpringerSharron H. Francis, Marco Conti, Miles D. Houslay, editors.
- v. 1- 2=, 2011 Springerv. 2, 2011 SpringerChristian Rommel, Bart Vanhaesebroeck, Peter K. Vogt, editors.Vol. 1 / (ix, 306 p.) -- v. 2. / (x, 301 p.).Also available: Print – v. 1- 2=, 2011
- 2015 WileySarah E. Edwards, Ines Rocha, Elizabeth M. Williamson, Michael Heinrich.Healthcare professionals, including doctors, pharmacists and nurses, are often confronted with patients who use over-the-counter (OTC) herbal medicinal products and food supplements. While taking responsibility for one's own health and treatment options is encouraged, many patients use these products based on limited (and sometimes inaccurate) information from non-scientific sources, such as the popular press and internet. There is a clear need to offer balanced, well-informed advice to patients, yet a number of studies have shown that, generally, conventionally trained health practitioners consider their knowledge about herbal medicinal products and supplements to be weak. Phytopharmacy fills this knowledge gap, and is intended for use by the busy pharmacist, nurse, or doctor, as well as the 'expert patient' and students of pharmacy and herbal medicine. It presents clear, practical and concise monographs on over a hundred popular herbal medicines and plant-based food supplements. Information provided in each monograph includes: Indications Summary and appraisal of clinical and pre-clinical evidence Potential interactions Contraindications Possible adverse effects An overview of the current regulatory framework is also outlined, notably the EU Traditional Herbal Medicinal Products Directive. This stipulates that only licensed products or registered traditional herbal medicinal products (THRs), which have assured quality and safety, can now legally be sold OTC. Monographs are included of most of the major herbal ingredients found in THRs, and also some plant-basedfood supplements, which while not strictly medicines, may also have the potential to exert a physiological effect.
- 2014 SpringerFabrizio Benedetti, Paul Enck, Elisa Frisaldi, Manfred Schedlowski, editors.Due to the recent explosion of placebo research at many levels the Editors believe that a volume on Placebo would be a good addition to the Handbook of Experimental Pharmacology series. In particular, this volume will be built up on a meeting on Placebo which will be held in Tuebingen (Germany) in January 2013, and where the most prominent researchers in this field will present and exchange their ideas. The authors who will be invited to write chapters for this volume will be the very same speakers at this meeting, thus guaranteeing high standard and excellence in the topic that will be treated. The approach of the book is mainly pharmacological, including basic research and clinical trials, and the contents range from different medical conditions and systems, such as pain and the immune system, to different experimental approaches, like in vivo receptor binding and pharmacological/behavioral conditioning. Overall, the volume will give an idea of modern placebo research, of timely concepts in both experimental and clinical pharmacology, as well as of modern methods and tools in neuroscience.
- 2009 SpringerAlexander V. Karasev, editor.Plant vaccines: an immunological perspective / D.C. Hooper -- Display of peptides on the surface of tobacco mosaic virus particles / M.L. Smith ... [et al.] -- Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality / S. Chebolu and H. Daniell -- Production of antibodies in plants: approaches and perspectives / K. Ko, R. Brodzik and Z. Steplewski -- Plant production of veterinary vaccines and therapeutics / R.W. Hammond and L.G. Nemchinov -- Plant-based oral vaccines: results of human trials / C.O. Tacket.
- 2015 SpringerJohn Papdopoulos, author ; David R. Schwartz, consulting editor.
- 2008 Springerb y John Papadopoulos.
- 2009 Springeredited by George Y. Wu, Achilles Pappano.
- 2016 Springeredited by George Y. Wu.
- 2013 SpringerFulltext Vol. 2 SpringerMichael S. Ritsner, editor.Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem.
- 2014 Wiley[edited by] Sarah R. Brown, Walter M. Gregory, Christopher Twelves, Julia Brown.
- 2014 SpringerDaria Mochly-Rosen, Kevin Grimes, editors.Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest.Also available: Print – 2014
- 2008 WHOA. Introduction -- B. Passive or active pharmacovigilance? -- C. Spontaneous reporting -- D. Cohort event monitoring -- E. Data processing -- F. Special types of event -- G. Relationship/causality assessment -- H. Signal identification -- I. Strengthening the signal -- J. Identifying risk factors -- K. Analyses -- L. Differences between spontaneous reporting and cohort event monitoring -- M. Organization -- N. Communication -- Annex.Also available: Print – 2008
- 2009 WHOWorld Health Organization.
- Practical pharmaceutics : an international guideline for the preparation, care and use of medicinal products2015 SpringerYvonne Bouwman-Boer, V'lain Fenton-May, Paul Le Brun, editors.Preface -- Introduction -- Prescription assessment -- Availability of medicines -- Oral solids -- Oral liquids -- Pulmonary -- Oropharynx -- Nose -- Ear -- Eye -- Rectal and vaginal -- Dermal -- Parenteral -- Irrigation and dialysis -- Product design -- Biopharmaceutics -- Quality risk management -- Physical chemistry -- Microbiology -- Statistics -- Radiopharmacy -- Stability -- Raw materials -- Containers -- Human resources -- Occupational health and safety -- Premises -- Equipment -- Basic operations -- Sterilisation methods -- Aseptic handling -- Quality requirements and analysis -- Documentation -- Production, Validation Quality Control -- Quality systems -- Logistics -- Instructions for the use of medicines -- Impact on Environment -- Information sources -- Index.
- 2015 SpringerGodrey Grech, Iris Grossman, editorsIntroduction -- Preventive and predictive genetics: a perspective -- Roadmap to drug development enabled by pharmacogenetics -- Pharmacogenetics, statistical considerations -- Pharmacokinetics and pharmacogenetics: bringing the magic bullet closer to reality -- Pharmacogenetics of adverse drug reactions -- Pharmacogenomics for haemoglobinopathies therapeutics -- Pharmacogenetics of neurodegenerative disorders -- Pharmacogenetics of asthma -- Pharmacogenetics and antineoplastic therapies -- Pharmacogenetics of coumarin anticoagulant therapy -- Implementation of genomic medicine: tools and challenges -- Ethical considerations in the genomic era -- Index.
- 2011 Springeredited by Frans P. Nijkamp and Michael J. Parnham.
- 2007edited by Harold Kalant, Denis M. Grant, Jane Mitchell.
- 2015 SpringerMichael K. Pugsley, Michael J. Curtis, editors.Preface -- Part 1. An Overview of Safety Pharmacology and its Role in Drug Discovery -- Part 2. The Safety Pharmacology Core Battery -- Part 3. Supplemental Safety Pharmacology -- Part 4. Safety Pharmacology of Biological and Anticancer Pharmaceuticals -- Part 5. Clinical Safety Pharmacology.
- v. 3, 1961.General editor: Börje Uvnäs.v. 1. Plenary session. Pharmacological control of release of hormones including antidiabetic drugs.--v. 2. Effects of drugs on synthesis and mobilization of lipids.--v. 3. New aspects of cardiac glycosides.--v. 4. Drugs and membranes.--v. 5. Methods for the study of pharmacological effects at cellular and subcellular levels.--v. 6. Metabolic factors controlling duration of drug action.--v. 7. Modern concepts in the relationship between structure and pharmacological activity.--v. 8. Pharmacological analysis of central nervous action.--v. 9. Bradykinin and vaso-dilating polypeptides. Pharmacology of the lung.--v. 10 Abstracts.
- v. 1-11, 1966.General editor: M. Rocha e Silva.v. 1. Mode of action of anti-parasitic drugs.--v. 2. Pharmacology of reproduction.--v. 3. Clinical pharmacology.--v. 4. Mechanisms of drug toxicity.--v. 5. The control of growth processes by chemical agents.--v. 6. Drugs in relation to blood coagulation haemostasis and thrombosis.--v. 7. Physico-chemical aspects of drug action.--v. 8. Salt and water balance.--v. 9. Pharmacology of pain.--v. 10. Monoamine oxidas inhibitors: relationship between pharmalogical clinical effects.--v. 11. Immunopharmacology.
- 2015 ScienceDirectVivekkumar K. Redasani, Sanjay B. Bari.Ch. 1. Introduction -- Ch. 2. Concept of prodrug -- Ch. 3. Types of prodrugs -- Ch. 4. Approaches for prodrugs -- Ch. 5. Applications -- Ch. 6. Role in drug discovery -- Ch. 7. Work reported -- Conclusion.
- 2007 SpringerValentino J. Stella ... [et al.], editors.
- v. 62-, 2005- SpringerAlso available: Print – v. 12-66, 1968-2008.
- Protective signaling in the myocardium : a role for protein kinase cepsilon and aldehyde dehydrogenase 2 regulators in the treatment of myocardial infarction and heart failure2010Lihan Sun.The nearly 9 million incidences of myocardial infarction (MI) and the resultant heart failure in the United States alone call for a continued need for the development of novel therapeutics. However, the molecular basis of these diseases is highly complex and awaits further elucidation. Our lab has a long-standing interest in determining the role of protein kinase C (PKC) in cardiovascular diseases. Elevated expression of alpha, beta, epsilon and deltaPKCs is associated with cardiac dysfunction in failing murine and human hearts. Moreover, genetic and pharmacological modulations of PKC activities exert profound impact on the state of these diseases. However, characterization of the specific role of each PKC isozyme was hampered by the lack of isozyme-selective PKC regulators. To this end, Mochly-Rosen and co-workers have rationally designed and developed isozyme-selective peptide activators and inhibitors of PKC that have enabled us to examine the role of each PKC isozyme in any biological system. Using an epsilonPKC-selective inhibitor, we found that sustained inhibition of epsilonPKC suppressed excessive cardiac fibrosis and preserved cardiac function in a rat model of hypertension-induced heart failure, in vivo. To uncover the mechanistic link between epsilonPKC and cardiac fibrosis, I showed that activation of epsilonPKC increased the activity matrix metalloproteinase-2 (MMP-2), a critical protease that degrades the extracellular matrix to facilitate cardiac fibrosis. Further, using the epsilonPKC inhibitor and cardiac fibroblasts that lack epsilonPKC, I discovered that histone deacetylase 6 (HDAC6), a cytosolic enzyme that deaceylates alpha-tubulin, participates in epsilonPKC modulation of MMP-2 activity during cardiac fibrosis. These results suggest that the epsilonPKC-selective inhibitor can be a potential therapeutic for the treatment of heart failure. Aldehyde dehydrogenase 2 (ALDH2) was identified by our group as a mitochondrial substrate for epsilonPKC that confers cardioprotection from ischemic injury. ALDH2 activation during MI is cardioprotective, because it oxidizes and thus removes toxic aldehydes that accumulate due to lipid peroxidation during ischemia-reperfusion. Since these aldehydes form protein adducts that inactive many cellular enzymes, they contribute to non-reversible damage to the ischemic myocardium. A recent study discovered that ALDH2 is required for nitroglycerin bioactivation, in vivo, but its enzymatic activity is inhibited by prolonged treatment with nitroglycerin. This has prompted us to determine potential risks associated with nitroglycerin tolerance in association with the role that ALDH2 has in cardiac protection. The clinical implications here are of special interest to us, because any risks pertinent to nitroglycerin treatment, if validated, can affect millions of patients with cardiac diseases. Therefore, I set off to determine whether sustained nitroglycerin treatment increases injury to the ischemic myocardium using a rat model of myocardial infarction (MI). I confirmed that sustained nitroglycerin treatment, as might be given to patients with angina pectoris, inhibited ALDH2 activity in the rat myocardium, in vivo. Further, I found that continuous treatment of nitroglycerin resulted in more than 2-fold increase in infarct size and worsened cardiac function after MI, in vivo. I then used Alda-1, a selective ALDH2 activator our group discovered, to assess whether activation of ALDH2 could undo the nitroglycerin-induced cardiac injury. Indeed, concomitant treatment with Alda-1 and nitroglycerin inhibited nitroglycerin-induced increase in infarct size and restored post-MI cardiac function. This finding poses a challenge to the prevalent clinical practice: patients, under sustained nitroglycerin therapy for the management of angina pectoris, are at risk of increased cardiac damage if they develop an MI during the nitroglycerin treatment. My animal studies suggest that if Alda-1 is given together with nitroglycerin, it can reduce cardiac damage caused by nitroglycerin tolerance. Finally, to determine the mechanism underlying the role of nitroglycerin and Alda-1 in MI injury, I demonstrated that Alda-1 prevented nitroglycerin-induced inactivation of ALDH2 and the resultant elevation of protein carbonylation, a hallmark of toxic aldehydic adducts, in the myocardium. The result substantiates a health mechanism for the heart: loss of control over oxidative stress leads to an injured myocardium and a simple correction of that function undoes the bad.
- 2008 SpringerEnno Klussmann, John Scott, editors ; contributors, E.M. Aandahl ... [et al.].
- 2013 SpringerMathias Jucker, Yves Christen, editors.The misfolding and aggregation of specific proteins is an early and obligatory event in many of the age-related neurodegenerative diseases of humans, and appears to occur many years before the onset of clinical symptoms. The initial cause of this pathogenic cascade and the means whereby disease spreads through the nervous system, remain uncertain. A recent surge of research, first instigated by pathologic similarities between prion disease and Alzheimer's disease, has increasingly implicated corruptive protein templating, or seeding, as a prime factor in the neurodegenerative process. The prion-like corruption of proteins also characterizes such clinically and etiologically diverse neurological disorders as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Understanding the misfolding, aggregation, trafficking and pathogenicity of affected proteins thus could reveal universal principles and common therapeutic targets for some of the most devastating and intractable human brain disorders.
- 2009 Springer Protocolsedited by S. Mohan Jain and Praveen K. Saxena.Establishment of adventitious root cultures of Echinacea purpurea for the production of caffeic acid derivatives / K.Y. Paek, H.N. Murthy and E.J. Hahn -- In vitro propagation of Rauwolfia serpentina using liquid medium, assessment of genetic fidelity of micropropagated plants, and simultaneous quantitation of reserpine, ajmaline, and ajmalicine / M.K. Goel ... [et al.] -- Medicinal properties, in vitro protocols and secondary metabolite analyses of Scots pine / H. Haggman ... [et al.] -- Saussurea medusa cell suspension cultures for flavonoid production / C.Z. Liu and P.K. Saxena -- Large-scale in vitro multiplication of Crataeva nurvala / S.B. Babbar, N. Walia and A. Kaur -- Bilberry in vitro protocols and analyses of phenolic compounds / L. Jaakola ... [et al.] -- In vitro propagation of two tuberous medicinal plants: Holostemma ada-kodien and Ipomoea mauritiana / S.P. Geetha ... [et al.] -- In vitro production of gymnemic acid from Gymnema sylvestre (Retz) R. Br. Ex Roemer and Schultes through callus culture under abiotic stress conditions / A.B. Ali Ahmed, A.S. Rao and M.V. Rao -- Establishment of plant regeneration and cryopreservation system from zygotic embryo-derived embryogenic cell suspension cultures of Ranunculus kazusensis / S.W. Kim and M.J. Oh -- In vitro culture and secondary metabolite isolation in bryophytes / A. Sabovljevic, M. Sabovljevic and N. Jockovic -- Micropropagation and in vitro conservation of vanilla (Vanilla planifolia Andrews) / M. Divakaran and K.N. Babu -- Protocol for in vitro regeneration and marker glycoside assessment in Swertia chirata Buch-Ham / S. Koul ... [et al.] -- Protocols for establishment of an in vitro collection of medicinal plants in the genus Scutellaria / I.B. Cole, F.T. Farooq and S.J. Murch -- Protocols for in vitro culture and phytochemical analysis of Phyllanthus species (Euphorbiaceae) / E. Catapan ... [et al.] -- In vitro clonal propagation of Asparagus racemosus, a high value medicinal plant / S. Saxena and N. Bopana -- Micropropagation of Penthorum chinense through axillary buds / J. Yang and Z.S. Peng -- Spontaneous plant regeneration and production of secondary metabolites from hairy root cultures of Centaurium erythraea Rafn / A. Subotic ... [et al.] -- Transgenic Hypericum perforatum / G. Franklin, M.M. Oliveira and A.C. Dias -- Agrobacterium-mediated transformation of Ruta graveolens L / K. Lievre ... [et al.] -- Gene expression profiling in Taxus baccata L. seedlings and cell cultures / K. Brun akova and J. Kosuth -- Catapol production in Chinese foxglove (Rehmannia glutinosa Libos.) hairy roots transformed with Agrobacterium rhizogenes ATCC15834 / S.J. Hwang -- Identification of medicinal plants and plant sequences: multiplexed MLPA assay / R.A. Barthelson -- Isolation of microsatellites from Catharanthus roseus (L.) G. Don using enriched libraries / S. Bhatia and B. Shokeen -- Production of cinnamyl glycosides in compact callus aggregate cultures of Rhodiola rosea through biotransformation of cinnamyl alcohol / Z. Gyorgy and A. Hohtola -- Spearmint plantlet culture system as a means to study secondary metabolism / B. Tisserat, M. Berhow and S.F. Vaughn -- Bioreactor production of secondary metabolites from cell cultures of periwinkle and sandalwood / J.V. Valluri -- Camptothecin production by in vitro cultures and plant regeneration in Ophiorrhiza species / T. Asano ... [et al.] -- Metabolomic analysis of Ocotea odorifera cell cultures: a model protocol for acquiring metabolite data / M. Maraschin ... [et al.] -- Production of 9-methoxycanthin-6-one from callus cultures of (Eurycoma longifolia Jack) Tongkat Ali / M. Maziah and N. Rosli -- Plant secondary metabolism in altered gravity / L.K. Tuominen, L.H. Levine and M.E. Musgrave -- The role of biotechnology in the production of the anticancer compound podophyllotoxin / H. Lata, C.S. Mizuno and R.M. Moraes.
- Quality assurance of pharmaceuticals : WHO guidelines, good practices, related guidance and GXP training materials.. Version 5.0.2015
- Quality assurance of pharmaceuticals : WHO guidelines, good practices, related regulatory guidance and GXP training materials.. Version 6.0.2016
- Quality assurance of pharmaceuticals : WHO guidelines, related guidance and GXP training materials, 20142014World Health Organization.
- 2015 SpringerFeroz Jameel, Susan Hershenson, Mansoor A. Khan, Sheryl Martin-Moe, editors.1 Challenges and Opportunities for Biotech Quality by Design -- 2 Lessons Learned From Monoclonal Antibody Applications to the Office of Biotechnology Products Quality by Design Pilot Program -- 3 Definitions and Scope of Key Elements of QbD -- 4 An Overview of Quality by Design for Drug Product -- 5 Development of Drug Product Formulations: Molecular Design and Early Candidates Screening -- 6 Approaches for Early Developability Assessment of Proteins to Guide Quality by Design of Liquid Formulations -- 7 Application of QbD Principles to Late-stage Formulation Development for Biological Liquid Products -- 8 Application of QbD Principles for Lyophilized Formulation Development -- 9 Drug Substance Frozen Storage and Thawing -- 10 Quality by Design as Applied to Drug Substance Formulation using Ultrafiltration and Diafiltration -- 11 A QbD Approach in the Development and Scale-up of Mixing Processes -- 12 Application of QbD Elements in the Development and Scale-up of a Commercial Filtration Process -- 13 Application of QbD Elements in the Development and Scale-up of Commercial Filling Process -- 14 Lyophilization Process Design and Development Using QbD Principles -- 15 Visible and Subvisible Protein Particle Inspection Within a QbD-based Strategy -- 16 Quality by Design for Distribution of Environmentally Sensitive Pharmaceutical Products -- 17 Quality by Design for Primary Container Components -- 18 Devices and Combination Products for Biopharmaceuticals -- 19 Applicability of QbD for Vaccine Drug Product Development -- 20 Automation and High Throughput Technologies in Biopharmaceutical Drug Product Development with QbD Approaches -- 21 Critical Quality Attributes, Specifications, and Control Strategy -- 22 Multivariate Analysis for Process Understanding, Monitoring, Control and Optimization in Lyophilization Processes -- 23 Using Mathematical Modeling and Prior Knowledge for QbD in Freeze-drying Processes -- 24 Application of Multivariate Statistical Process Monitoring to Lyophilization Process -- 25 Application of PAT in Real-time Monitoring and Controlling of Lyophilization Process -- 26 Product Homogeneity Assessment during Validation of Biopharmaceutical Drug Product Manufacturing Processes -- 27 Application of Quality by Design Principles to the Drug Product Technology Transfer Process -- 28 Regulatory Considerations For Implementation of the QbD Paradigm for Biologics: Laying the Foundation for Product and Process Lifecycle Management.
- 2010 WHOAlso available: Print – 2010
- 2010 CRCnetBASEYvonne Connolly Martin.Overview of quantitative drug design -- Noncovalent interactions in biological systems -- Preparation of 3D structures of molecules for 3D QSAR -- Calculating physical properties of molecules -- Biological data -- Form of equations that relate potency and physical properties -- Statistical basis of regression and partial least-squares analysis -- Strategy for the statistical evaluation of a data set of related molecules -- Detailed examples of QSAR calculations on erythromycin esters -- Case studies -- Methods to approach other structure-activity problems.
- 2011 CRCnetBASELawrence E. Williams."This comprehensive overview details the process of radiopharmaceutical development, from cellular studies to animal experiments to the design and implementation of clinical trials. It examines the relative benefits of various radiopharmaceuticals and provides guidance on dose estimation and agent selection. Utilizing figures of merit for quantitative assessment, it covers standard medical internal radiation dose (MIRD), absorbed dose method for imaging agents, vivo methods for obtaining activity data, errors of activity estimation techniques, phantom-based and patient-based dose estimates and their associated uncertainties, and options available to clinical physicists. Supported by numerous examples from clinical trials, it discusses two and three dimensional estimation processes, including modern hybrid scanners such as SPECT/CT and PET/CT"--Provided by publisher.
- 2008 Springerby Monica Baia, Simion Astilean, Traian Iliescu.
- 2012 Springeredited by William S. Spielman, Narayanan Parameswaran.Introduction to RAMPs / Narayanan Parameswaran and William S. Spielman -- RAMPs and CGRP receptors / James Barwell ... [et al.] -- Regulation of GPCR trafficking by RAMPs / Jennifer M. Bomberger, Narayanan Parameswaran, and William S. Spielman -- Regulation of calcium sensing receptor trafficking by RAMPs / Tristan Bouschet, Støphane Martin, and Jeremy M. Henley -- Understanding RAMPs through genetically engineered mouse models / Mahita Kadmiel, Kimberly L. Fritz, and Kathleen M. Caron -- RAMPs as drug targets / Patrick M. Sexton ... [et al.] -- RAMP like proteins : RTP and reep family of proteins / Joel Mainland and Hiroaki Matsunami -- Regulation of RAMP expression in diseases / Asha Jacob, Rongqian Wu, and Ping Wang -- Perspectives on some recent studies on RAMPs / Narayanan Parameswaran and William S. Spielman.Also available: Print – 2012
- 2016 ClinicalKeyH.P. Rang, J.M. Ritter, R.J. Flower, G. Henderson.What is pharmacology? -- How drugs act : general principles -- How drugs act : molecular aspects -- How drugs act : cellular aspects, excitation, contraction and secretion -- Cell proliferation, apoptosis, repair and regeneration -- Cellular mechanisms : host defence -- Method and measurement in pharmacology -- Absorption and distribution of drugs -- Drug metabolism and elimination -- Pharmacokinetics -- Individual variation, pharmacogenomics and personalised medicine -- Chemical mediators and the autonomic nervous system -- Cholinergic transmission -- Noradrenergic transmission -- 5-Hydroxytryptamine and the pharmacology of migraine -- Purines -- Local hormones 1 : histamine and the biologically active lipids -- Local hormones 2 : peptides and proteins -- Cannabinoids -- Nitric oxide and related mediators -- The heart -- The vascular system -- Atherosclerosis and lipoprotein metabolism -- Haemostasis and thrombosis -- Haemopoietic system and treatment of anaemia -- Anti-inflammatory and immunosuppressant drugs -- Skin -- Respiratory system -- The kidney and urinary system -- The gastrointestinal tract -- The control of blood glucose and drug treatment of diabetes mellitus -- Obesity -- The pituitary and the adrenal cortex -- The thyroid -- The reproductive system -- Bone metabolism -- Chemical transmission and drug action in the central nervous system -- Amino acid transmitters -- Other transmitters and modulators -- Neurodegenerative diseases -- General anaesthetic agents -- Analgesic drugs -- Local anaesthetics and other drugs affecting sodium channels -- Anxiolytic and hypnotic drugs -- Antiepileptic drugs -- Antipsychotic drugs -- Antidepressant drugs -- CNS stimulants and psychotomimetic drugs -- Drug addiction, dependence and abuse -- Basic principles of antimicrobial chemotherapy -- Antibacterial drugs -- Antiviral drugs -- Antifungal drugs -- Antiprotozoal drugs -- Anthelmintic drugs -- Anticancer drugs -- Harmful effects of drugs -- Lifestyle drugs and drugs in sport -- Biopharmaceuticals and gene therapy -- Drug discovery and development.
- 2007H.P. Rang, M.M. Dale, J.M. Ritter, R.J. Flower.
- 2012 ClinicalKeyH P Rang, M M Dale, J M Ritter, R J Flower and G Henderson.This edition sets out a clear route through pharmacology for the reader, from a molecular understanding of receptors and drug actions to the clinical use of the most important groups of drugs. It contains everything students need to know about pharmacology in their early years.
- 2012 Springer Protocolsedited by Yi Zheng.On setting up and assessing docking simulations for virtual screening / Jacek Biesiada, Aleksey Porollo, and Jaroslaw Meller -- Virtual ligand screening combined with NMR to identify Dvl PDZ domain inhibitors targeting the Wnt signaling / Jufang Shan and Jie J. Zheng -- Rational design of Rho GTPase-targeting inhibitors / Xun Shang and Yi Zheng -- Rational design of peptide ligands against a glycolipid by NMR studies / Wenyong Tong [and others] -- Combinatorial strategy for the acquisition of potent and specific protein tyrosine phosphatase inhibitors / Sheng Zhang [and others] -- Identification of allosteric inhibitors of p21-activated kinase / Julien Viaud and Jeffrey R. Peterson -- Using a modified yeast two-hybrid system to screen for chemical GEF inhibitors / Anne Blangy and Philippe Fort -- Random mutagenesis of peptide aptamers as an optimization strategy for inhibitor screening / Nathalie Bouquier [and others] -- Screening strategy for trapping the inactive conformer of a dimeric enzyme with a small molecule inhibitor / Charles S. Craik and Tina Shahian -- Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1 / Valerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi -- Affinity purification of protein kinases that adopt a specific inactive conformation / Pratistha Ranjitkar and Dustin J. Maly -- Determination of the kinetics and thermodynamics of ligand binding to a specific inactive conformation in protein kinases / Sanjay B. Hari, Pratistha Ranjitkar, and Dustin J. Maly -- Purification and specific assays for measuring APE-1 endonuclease activity / Adrian Esqueda [and others] -- In vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents / Mohammad Azam -- Utilizing antagomiR (antisense microRNA) to knock down microRNA in murine bone marrow cells / Chinavenmeni S. Velu and H. Leighton Grimes -- Synthesis, conjugation, and labeling of multifunctional pRNA nanoparticles for specific delivery of siRNA, drugs, and other therapeutics to target cells / Peixuan Guo [and others] -- Mouse models for tumor metastasis / Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang.
- 2010 SpringerKurt Hellmann, Walter Rhomberg, editors."Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer's disease could be stabilized by one or both these drugs."--P.  of cover.
- 2014 SpringerJagdish N. Sharma, editor.Basic and clinical aspects of bradykinin receptor antagonists -- The kallikrein-kinin pathways in hypertension and diabetes -- Tissue Kallikrein-kinin therapy in hypertension and organ damage -- Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension -- The Kallikrein-kinin system in diabetic retinopathy -- Genetic manipulation and genetic variation of the Kallikrein Kinin System; impact on cardiovascular and renal diseases.
- 2013 Cambridgeedited by George J. Christ, Karl-Erik Andersson."Regenerative medicine is broadly defined as the repair or replacement of damaged cells, tissues, and organs. It is a multidisciplinary effort in which technologies derive from the fields of cell, developmental, and molecular biology; chemical and material sciences (i.e., nanotechnology); engineering; surgery; transplantation; immunology; molecular genetics; physiology; and pharmacology. As regenerative medicine technologies continue to evolve and expand across the boundaries of numerous scientific disciplines, they remain at the forefront of the translational research frontier with the potential to radically alter the treatment of a wide variety of disease and dysfunction. The goal of this book is to draw attention to the critical role that the pharmacological sciences will undeniably play in the advancement of these treatments. This book is invaluable for advanced students, postdoctoral fellows, researchers new to the field of regenerative medicine/tissue engineering, and experienced investigators looking for new research avenues. This is the first state-of-the-art book in this rapidly evolving field of research"--Provided by publisher.
- 2016 Kargervolume editors, Quan Dong Nguyen, Eduardo B. Rodrigues, Michel Eid Farah, William F. Mieler, Diana V. Do.
- 2015 Springer Protocolsedited by Mouldy Sioud.RNA interference : mechanisms, technical challenges, and therapeutic opportunities / Mouldy Sioud -- Nanostructured RNAs for RNA interference / Yuko Nakashima [and others] -- One long oligonucleotide or two short oligonucleotides based shRNA construction and expression / Xue-jun Wang and Sheng-qi Wang -- PLGA microspheres encapsulating siRNA / Giuseppe De Rosa and Giuseppina Salzano -- Magnetic nanoparticle and magnetic field assisted siRNA delivery in vitro / Olga Mykhaylyk [and others] -- Cytoplasmic delivery of siRNAs to monocytes and dendritic cells via electroporation / Mouldy Sioud -- Delivery of siRNAs to cancer cells via bacteria / Omar Ahmed, Andrea Krühn, and Hermann Lage -- Microwell array-mediated delivery of lipoplexes containing nucleic acids for enhanced therapeutic efficacy / Yun Wu, Daniel Gallego-Perez, and L. James Lee -- Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy / Karin Zins [and others] -- Targeted in vivo delivery of siRNA and an endosome- releasing agent to hepatocytes / Magdolna G. Sebestyén [and others] -- Cell-internalization SELEX : method for identifying cell- internalizing RNA aptamers for delivering siRNAs to target cells / William H. Thiel [and others] -- Strategies for siRNA navigation to desired cells / Mouldy Sioud -- Use of guanidinopropyl-modified siRNAs to silence gene expression / Maximilian C.R. Buff [and others] -- Therapy of respiratory viral infections with intranasal siRNAs / Sailen Barik and Patrick Lu -- Engineering therapeutic cancer vaccines that activate antitumor immunity / Per Ole Iversen and Mouldy Sioud -- Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses / Mouldy Sioud, Anne Mobergslien, and Stein Sæbøe-Larssen -- Targeting bcr-abl transcripts with siRNAs in an imatinib- resistant chronic myeloid leukemia patient : challenges and future directions / Michael Koldehoff -- Facile method for interfering with off-target silencing mediated by the sense strand / Anne Mobergslien and Mouldy Sioud -- Overcoming the challenges of siRNA activation of innate immunity : design better therapeutic siRNAs / Mouldy Sioud -- Gene silencing in vitro and in vivo using intronic microRNAs / Jia Han Deng [and others] -- In silico identification of novel endo-siRNAs / Andrew Schuster [and others] -- Computer-assisted annotation of small RNA transcriptomes / Nicole Ortogero [and others] -- miR-CATCH : microRNA capture affinity technology / Sebastian Vencken [and others] -- Roles of MicroRNAs in cancers and development / Shigeru Takasaki -- Targeting microRNAs to withstand cancer metastasis / Valentina Profumo [and others] -- Urinary microRNAs as a new class of noninvasive biomarkers in oncology, nephrology, and cardiology / Hana Mlcochova [and others] -- Magnetic bead-based isolation of exosomes / Morten P. Oksvold, Axl Neurauter, and Ketil W. Pedersen -- Modified 2'-ribose small RNAs function as toll-like receptor-7/8 antagonists / Mouldy Sioud.
- 2013 SpringerJose Russo, Irma H. Russo.This book is designed for advanced students and researchers in cell biology, biochemistry, molecular biology, medicine in general, and cancer in particular. It provides the latest data on the transcriptome of the mammary gland in order to establish the molecular and cellular biology of differentiation leading to cancer prevention. The authors have based their work on the epidemiological evidence that early first full term pregnancy is a protective factor in humans against breast cancer and using this knowledge have developed in vivo and in vitro experimental systems that have demonstrated mechanistically how the differentiation takes place. The transcriptoma analysis of the female breast shows that an early first full term pregnancy reprograms the organ by imprinting a genomic signature that differs according to reproductive history. This reprogramming takes place at the chromatin level by changing the transcriptional process. The modification of the transcriptional control is due to the expression of non-coding RNA sequences and post-transcriptional control driven by the spliceosome. The plasticity of the genome of the human breast makes possible this reprogramming that is not only induced by the physiological process of pregnancy but by the use of hormones mimicking pregnancy. The role of stem cells and their reprogramming during differentiation are presented as a new paradigm in breast cancer prevention.
- Safety of medicines : a guide to detecting and reporting adverse drug reactions : why health professionals need to take action2002 WHO[prepared by V.K. Lepakhin].Briefly covers the importance of voluntary reporting on adverse drug reactions (ADR). Highlights include why pharmacovigilance is needed in every country, how ADRs can influence labelling, and prevent new medicine tragedies from developing.
- Safety pharmacology in pharmaceutical development : approval and post marketing surveillance. 2nd ed.2012 CRCnetBASEShayne C. Gad."This book covers the regulatory required evaluation and study of the potentially adverse pharmacological effects of new drugs, from the general regulatory requirements to the specific studies that must be done and how they are performed and interpreted. Based on more than 30 years of direct experience, the author describes tricks and practical insights for making studies work and understanding why they don't. The second edition includes current regulations (US FDA and international especially Europe and Japan) and updated test methods, interpretation, and science"--Provided by publisher.
- 2013William Hazen Parsons.Voltage-gated sodium channels (NaV) serve an essential role in physiology. Accordingly, their dysfunction is associated with a number of human diseases and disorders, including epilepsy, cardiac arrhythmias, and chronic pain conditions. Designed by Nature as a chemical weapon, the naturally occurring channel blocker (+)-saxitoxin (STX) can be repurposed as a tool for studying these large integral membrane proteins. Access to new toxin derivatives through de novo synthesis offers a unique strategy to probe NaV structure and function, circumventing key limitations associated with existing methods for studying these proteins. The preparation and electrophysiological evaluation of an expanded library of N21-modified STX analogues is described herein. Characterization of the binding properties of these nanomolar NaV inhibitors has contributed to the development of an enhanced model for the structure of the inner pore of the channel. A select set of STX-fluorophore conjugates that bind reversibly to NaV with submicromolar potency serve as fluorescent markers of channels in living cells to study channel motility in the cell membrane. By contrast, maleimide-conjugated STX derivatives can be engineered to act as irreversible inhibitors of ion conductance when applied to wild-type NaV isoforms. The unique binding behavior of these derivatives has been leveraged to develop a new class of NaV probes for use in live cell imaging experiments and protein profiling studies. Maleimide-toxin conjugates with bioorthogonal reactive groups have been synthesized and can be employed for ligation of visualization and isolation tags to covalently modified channels. Appendage of fluorine-18 to a modified STX affords a probe for studying NaV expression in living subjects. An efficient synthetic route yields a derivative that binds with nanomolar affinity to several NaV isoforms. Biodistribution, autoradiography, and PET-MRI imaging studies demonstrate accumulation of the radiotracer at the site of injury in a rat model of neuropathic pain. This uptake correlates with the previously reported upregulation of NaV isoforms at this site, validating the utility of this probe as a NaV imaging agent. Collectively, these STX derivatives, uniquely available through chemical synthesis, represent a novel set of molecular probes for studying NaV function in vitro and in vivo.
- 2008 Springeredited by J.M. Monti ... [et al.].
- 2008 ScienceDirectedited by Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito.
- 2013 SpringerVera Regitz-Zagrosek, editor.This is the very first book to deal with sex and gender differences in drug therapy - an increasingly recognized medical need. It starts with an overview on S/G in clinical syndromes and a documentation of the medical and socioeconomic damage caused by gender specific adverse drug effects. Part I covers S/G differences in pharmacokinetics. Researchers will be satisfied by the detailed discussion of the mechanisms of S/G differences in drug effects that represents cutting edge science and includes interaction of drugs with sex hormones, genomic and epigenetic mechanisms. It also covers S/G in drug development, in animal models and clinical development and S/G in drug prescriptions. Part II targets S/G differences in drug effects in cardiovascular, pulmonary, CNS, neuromuscular, neuropsychiatric and metabolic diseases, in cancer, inflammation, and rheumatic diseases, in bacterial and retroviral infections, thrombosis, embolism. New drugs will be discussed.
- 2013 SpringerMario A. Dicato, editor.Drug Interactions and Pharmacogenetics -- Breast Cancer -- Lung Cancer -- Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment -- Gynecologic Cancer -- Genitourinary Cancer -- Central Nervous System -- Bone Marrow Toxicity: Red Blood Cells -- Bone Marrow Toxicity: White Blood Cells -- Dermatologic Side Effects of Systemic Anticancer Therapy -- Myeloid Malignancies -- Lymphoma -- Multiple Myeloma -- Preservation of Fertility in the Cancer Patient -- Cardiotoxicity -- Toxicity of Bone-Targeted Agents in Malignancy -- State of the Art of Antiemetic Therapy -- Side Effects of Nociceptive Cancer Pain Treatments in Adults -- Totally Implanted Access Ports: Indications and Prevention of Complications.
- 2008 Springeredited by Leoni Villano Bonamin.
- 2011 SpringerVitomir Šunjić, Michael J. Parnham.
- 2007 Springer[edited by] Patrick Augustijns, Marcus Brewster.
- 2013 SpringerErich Gulbins, Irina Petrache, editors.Sphingolipids are lipid components of the plasma membrane in eukaryotic cells. They have an important function in signaling mechanisms in the cell. This book on sphingolipids provides insights into the basics of sphingolipid biology and drug development, with a particular emphasis on the sphingolipid derivative ceramide. In the first part basic functions of sphingolipids are described, as well as the genetics of important enzymes, sphingolipid metabolism and synthesis. The second part of this first volume focuses on drug development and pharmacology. The book is intended for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians working in pharmacology, oncology, cardiology, neurology and infectious disease. Together with Volume 216 by the same editors, the collection represents a unique, comprehensive work on sphingolipids, providing information on both sphingolipids' basic biology (including synthesis, metabolism and cell biology) and their important function in a (patho-)physiological context.
- 2013 SpringerErich Gulbins, Irina Petrache, editors.Sphingolipids in Cancer. Sphingosine Kinase/Sphingosine 1-Phosphate Signaling in Cancer Therapeutics and Drug Resistance / Shanmugam Panneer Selvam, Besim Ogretmen -- Using ASMase Knockout Mice to Model Human Diseases / Guoqiang Hua, Richard Kolesnick -- New Perspectives on the Role of Sphingosine 1-Phosphate in Cancer / Susan Pyne, Nigel J. Pyne -- Sphingolipids and Response to Chemotherapy / Marie-Thérèse Dimanche-Boitrel, Amélie Rebillard -- Lung Cancer and Lung Injury: The Dual Role of Ceramide / Tzipora Goldkorn, Samuel Chung, Simone Filosto -- Sphingolipids' Role in Radiotherapy for Prostate Cancer / Carla Hajj, Adriana Haimovitz-Friedman -- Sphingolipids in Cardio-Reno-vascular Diseases. Sphingolipid Metabolism and Atherosclerosis / Xian-Cheng Jiang, Jing Liu -- Cardiovascular Effects of Sphingosine-1-Phosphate (S1P) / Bodo Levkau -- Cross Talk Between Ceramide and Redox Signaling: Implications for Endothelial Dysfunction and Renal Disease / Pin-Lan Li, Yang Zhang -- Sphingolipids in Inflammation, Infection and Lung Diseases. Sphingolipids in Lung Endothelial Biology and Regulation of Vascular Integrity / Taimur Abbasi, Joe G. N. Garcia -- Sphingolipids in Acute Lung Injury / Stefan Uhlig, Yang Yang -- The Involvement of Sphingolipids in Chronic Obstructive Pulmonary Diseases / Irina Petrache, Daniela N. Petrusca -- Ceramide in Cystic Fibrosis / Heike Grassmé, Joachim Riethmüller, Erich Gulbins -- Regulation of the Sphingosine Kinase/Sphingosine 1-Phosphate Pathway / K. Alexa Orr Gandy, Lina M. Obeid -- Bacterial Infections and Ceramide / Heike Grassmé, Katrin Anne Becker -- Viral Infections and Sphingolipids / Jürgen Schneider-Schaulies, Sibylle Schneider-Schaulies -- Ceramide in Plasma Membrane Repair / Annette Draeger, Eduard B. Babiychuk -- Sphingolipids and Inflammatory Diseases of the Skin / Burkhard Kleuser, Lukasz Japtok -- Sphingolipids in Obesity, Type 2 Diabetes, and Metabolic Disease / S. B. Russo, J. S. Ross, L. A. Cowart -- Sphingolipids in Neuro-psychiatry and Muscle Diseases. Neuronal Forms of Gaucher Disease / Einat B. Vitner, Anthony H. Futerman Sphingolipids in Neuroinflammation / Laura Davies, Klaus Fassbender, Silke Walter -- Sphingolipids in Psychiatric Disorders and Pain Syndromes / C. Mühle, M. Reichel, E. Gulbins, J. Kornhuber -- Role of Sphingosine 1-Phosphate in Skeletal Muscle Cell Biology / Paola Bruni, Chiara Donati.
- 2014 SpringerMichael B.A. Oldstone, Hugh Rosen, editors."This volume focuses on the role of sphingosine-1-phosphate (S1P) and its analogs in the induced sequestration of lymphocytes in secondary lymphoid organs or in the microenvironment of tissues involved in infection or autoimmune disease. Initial chapters define the pathways to understand S1P signaling. They cover the organization of signaling systems, the structural biology of the S1P1 receptor, and the chemical and genetic tools that are available and useful to explore this area of research and therapeutics. The later chapters highlight S1P and endothelial integrity, lymphocyte migration in the spleen, and S1P agonist in controlling immunopathologic manifestations of acute respiratory influenza virus infection (in the lung), and its accompanying cytokine storm as well as immunopathologic disease of the central nervous system, including the beginning of treatments in multiple sclerosis. One chapter reveals the possible involvement of other lipid molecules, their use for better understanding lipid signaling, and their potential in the modulation of immune responses."--Publisher's website.Also available: Print – 2014
- 2013 SpringerParag Kolhe, Mrinal Shah, Nitin Rathore, editors.This comprehensive book encompasses various facets of sterile product development. Key concepts relevant to the successful development of sterile products are illustrated through case studies and are covered under three sections in this book: Formulation approaches that discuss a variety of dosage forms including protein therapeutics, lipid-based controlled delivery systems, PEGylated biotherapeutics, nasal dosage form, and vaccines, Process, container closure and delivery considerations including freeze-thaw process challenges, best practices for technology transfer to enable commercial product development, innovations and advancement in aseptic fill-finish operations, approaches to manufacturing lyophilized parenteral products, pen / auto-injector delivery devices, and associated container closure integrity testing hurdles for sterile product closures, Regulatory and quality aspects in the areas of particulate matter and appearance evaluation, sterile filtration, admixture compatibility considerations, sterilization process considerations, microbial contamination investigations and validation of rapid microbiological methods, and dry and moist heat sterilizers This book is a useful resource to scientists and researchers in both industry and academia, and it gives process and product development engineers insight into current industry practices and evolving regulatory expectations for sterile product development.
- 2015Pamela Flood, MD, MA, Professor of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Palo Alto, California ; James P. Rathmell, MD, Executive Vice Chair and Chief, Division of Pain Medicine, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Henry Knowles Beecher Professor of Anaesthesia, Harvard Medical School, Boston, Massachusetts ; Steven Shafer, MD, professor of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Palo Alto, California.PART I: Basic principles of physiology and pharmacology -- Basic principles of physiology / Pamela Flood, Seven Shafer -- Basic principles of pharmacology / Pamela Flood, Seven Shafer -- PART II: Neurologic system -- Neurophysiology / Pamela Flood, Seven Shafer -- Inhaled anesthetics / Pamela Flood, Seven Shafer -- Intravenous sedatives and hypnotics / James P. Rathmell, Carl E. Rosow -- Pain physiology / Hui Yang, Bihua Bie, Mohamed A. Naguib -- Opioid agonists and antagonists / Kenneth Cumming III, Mohamed A. Naguib -- Centrally acting nonopioid analgesics / Hesham Elsharkawy, Mohamed A. Naguib -- Peripherally acting analgesics / Hesham Elsharkawy, Mohamed A. Naguib -- Local anesthetics / Kamal Maheshwari, Mohamed A. Naguib -- Neuromuscular physiology / Mohamed A. Naguib -- Neuromuscular blocking drugs and reversal agents / Mohamed A. Naguib -- Antiepileptic and other neurologically active drugs / Pamela Flood, Mark Burbridge -- PART III: Circulatory system -- Circulatory physiology / James Ramsay, Barrett Larson -- Cardiac physiology / Sumeet Goswami, Bessie Kachulis, Teresa A. Mulaikal, Jack S. Shanewise -- Renal physiology / Jonathan Hastie, Jack S. Shanewise -- Intravenous fluids and electrolytes / Jessica Spellman, Jack S. Shanewise -- Sympathomimetic drugs / Sansan S. Lo, Jack S. Shanewise -- Sympatholytics / Steven Miller -- Vasodilators / James Ramsay, Carter Peatross -- Antiarrhythmic drugs / James Ramsay, Nicholas Anast -- Diuretics / Maya Jalbout Hastie, Jack S. Shanewise -- Lipid-lowering drugs / Sarah C. Smith, Jack S. Shanewise -- PART IV: Pulmonary system -- Gas exchange / Peter Slinger -- Respiratory pharmacology / Peter Slinger -- Acid-base disorders / Peter Slinger -- PART V: Blood and hemostasis -- Physiology of blood and hemostasis / Jerrold H. Levy -- Blood products and blood components / Jerrold H. Levy -- Procoagulants / Jerrold H. Levy -- Anticoagulants / Jerrold H. Levy -- Physiology and management of massive transfusion / Jerrold H. Levy -- PART VI: Gastrointestinal system and metabolism -- Gastrointestinal physiology / Michael J. Murray -- Metabolism / Michael J. Murray -- Antiemetics / Michael J. Murray, David A. Grossblatt -- Gastrointestinal motility drugs / Michael J. Murray, Jillian A. Maloney -- Nutrition / Michael J. Murray -- PART VII: Endocrine system -- Normal endocrine function / Vivek K. Moitra -- Drugs that alter glucose regulation / Vivek K. Moitra -- Drugs for the treatment of hypothyroidism and hyperthyroidism / Vivek K. Moitra -- Other endocrine drugs / Vivek K. Moitra -- PART VIII: Miscellaneous -- Antimicrobials, antiseptics, disinfectants, and management of perioperative infection / Pamela Flood -- Chemotherapeutic drugs / James P. Rathmell, Mihir M. Kamdar -- Drugs used for psychopharmacologic therapy / Joseph Kwok, Pamela Flood -- PART IX: Special populations -- Physiology of the newborn / Pamela Flood -- Maternal and fetal physiology and pharmacology / Pamela Flood -- Physiology and pharmacology of the elderly / Pamela Flood -- Physiology and pharmacology of resuscitation / Michael J. Murray.
- 2015 Knoveledited by Marcos Luciano Bruschi.
- 2013 Future MedThomas Bieber.Stratified medicine : a new challenge for academia, industry, regulators and patients -- Stratified medicine : a new era in the therapeutic approach -- Challenges for academic medicine and clinicians -- Challenges for diagnostics industry -- Challenges for the pharmaceutical industry -- Separate or codevelopment of biomarker and drug : the scenarios -- Challenges for the regulatory agencies in establishing an environment favorable for stratified medicine -- Challenges for the patients facing stratified medicine & personal genomics -- Conclusions & outlook to the future health system -- Stratified medicine : a challenging social experiment.
- 2014 Springer Protocolsedited by Wayne F. Anderson.Data Management in the Modern Structural Biology and Biomedical Research Environment -- Structural Genomics of Human Proteins -- Target Selection for Structural Genomics of Infectious Diseases -- Selecting Targets from Eukaryotic Parasites for Structural Genomics and Drug Discovery -- High Throughput Cloning for Biophysical Applications -- Expression and Solubility Testing in a High Throughput Environment -- Protein Production for Structural Genomics Using E. coli Expression -- Eukaryotic Expression Systems for Structural Studies -- Automated Cell-free Protein Production Methods for Structural Studies -- Parallel Protein Purification -- Oxidative Refolding from Inclusion Bodies -- High throughput Crystallization Screening -- Screening Proteins for NMR Suitability -- Salvage or Recovery of Failed Targets by in situ Proteolysis -- Salvage of Failed Protein Targets by Reductive Alkylation -- Salvage or Recovery of Failed Targets by Mutagenesis to Reduce Surface Entropy -- Data Collection for Crystallographic Structure Determination -- Structure, Determination, Refinement, and Validation -- Virtual High-Throughput Ligand Screening -- Ligand Screening using Fluorescence Thermal Shift Analysis (FTS) -- Ligand Screening using Enzymatic Assays -- Ligand Screening using NMR -- Screening Ligands by X-ray Crystallography -- Case Study Structural Genomics and Human Protein Kinases.
- 2007 Springeredited by Harren Jhoti, Andrew R. Leach.
- 2012 Springer Protocolsedited by Leslie W. Tari.The utility of structural biology in drug discovery / Leslie W. Tari -- Genetic construct design and recombinant protein expression for structural biology / Suzanne C. Edavettal, Michael J. Hunter, and Ronald V. Swanson -- Purification of proteins for crystallographic applications / Daniel C. Bensen -- Protein crystallization for structure-based drug design / Isaac D. Hoffman -- X-ray sources and high-throughput data collection methods / Gyorgy Snell -- The use of molecular graphics in structure-based drug design / Paul Emsley and Judit É. Debreczeni -- Crystallographic fragment screening / John Badger -- The role of enzymology in a structure-based drug discovery program : bacterial DNA gyrase / Mark L. Cunningham -- Leveraging structural information for the discovery of new drugs : computational methods / Toan B. Nguyen, Sergio E. Wong, and Felice C. Lightstone -- Chemical informatics : using molecular shape descriptors in structure-based drug design / Andy Jennings -- Accounting for solvent in structure-based drug design / Leslie W. Tari -- Structure-based drug design on membrane protein targets : human integral membrane protein 5-lipoxygenase-activating protein / Andrew D. Ferguson -- Application of SBDD to the discovery of new antibacterial drugs / John Finn -- Leveraging SBDD in protein therapeutic development : antibody engineering / Gary L. Gilliland [and others] -- A medicinal chemistry perspective on structure-based drug design and development / Shawn P. Maddaford.
- Superbugs and superdrugs : a history of MRSA : the transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 11 July 20062008 Wellcome Trustedited by L.A Reynolds and E.M. Tansey.
- 2006 ScienceDirectR.S. Vardanyan, V.J. Hruby.
- 2012 SpringerAleš Prokop, Seth Michelson.
- 2016 SpringerDonald E. Mager, Holly H.C. Kimko, editors.
- 2013 SpringerPhilipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan.Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
- 2013 Springer Protocolsedited by Jürgen Moll, Riccardo Colombo.The path to oncology drug target validation : an industry perspective -- Identification of aptamers as specific binders and modulators of cell-surface receptor activity -- The design and structure-functional properties of DNA-based immunomodulatory sequences -- SiRNA design principles and off-target effects -- Western blot evaluation of siRNA delivery by ph-responsive peptides -- High-throughput RNAi screening for the identification of novel targets -- Integration of RNAi and small molecule screens to identify targets for drug development -- CellProfiler and KNIME : Open source tools for high content screening -- PARP inhibition as a prototype for synthetic lethal screens -- Structure-based target druggability assessment -- Validating pharmacological disruption of protein-protein interactions by acceptor photobleaching FRET imaging -- Systematic analysis of complex signal transduction pathways using protein fragment complementation assays -- Reverse phase protein microarrays and their utility in drug development -- A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization -- Two-dimensional vs. Three-dimensional in vitro tumor migration and invasion assays -- Tumor spheroid-based migration assays for evaluation of therapeutic agents -- The neurosphere assay applied to neural stem cells and cancer stem cells -- Genetically engineered animal models for in vivo target identification and validation in oncology -- Target validation in mice by constitutive and conditional RNAi -- In vivo target validation by inducible RNAi in human xenograft mouse models -- Bright-field in situ hybridization methods to discover gene amplifications and rearrangements in clinical samples -- Combined microRNA in situ hybridization and immunohistochemical detection of protein markers.
- 2015 SpringerMichael Andreeff, editor.This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia.
- 2012Elizabeth Josephine Beans.The theme of this work is to utilize hypothesis driven synthetic manipulation to enhance our understanding of the biological effects of prostratin and its highly potent analogs, and to utilize this understanding for the improvement of the therapeutic properties thereof. Prostratin, a natural product activator of protein kinase C (PKC), is a molecule of interest for targeting latent HIV, the primary obstacle to HIV eradication in infected individuals on effective highly active antiretroviral therapy. Chapter one describes the current state of the HIV pandemic, therapeutic strategies, prospects for a cure, and clinical studies toward immune activation therapy. Chapter two is a seminal and complete analysis of the biological effects of prostratin, a natural product candidate for immune activation therapy. Chapter three presents the design, synthesis, and evaluation of highly potent analogs of prostratin via an efficient semi-synthetic route. Chapter four presents the design and synthesis of isotopically labeled prostratin analogs to be utilized in solid-state NMR studies probing the active conformation of the PKC/activator complex in its membrane associated state. Chapter five presents the design, synthesis, and evaluation of prodrugs of prostratin and prostratin analogs for the optimization of pharmacologic properties.
- 19??.issued by the Scientific Department of the Sandoz Chemical Works.
- 2009 SpringerKeiko Hiyama, editor.
- 2009 SpringerKewal K. Jain.Basics of Personalized Medicine -- Molecular Diagnostics as Basis of Personalized Medicine -- Role of Biomarkers in Personalized Medicine -- Pharmacogenetics -- Pharmacogenomics -- Role of Pharmacoproteomics -- Role of Metabolomics in Personalized Medicine -- Personalized Biological Therapies -- Development of Personalized Medicine -- Personalized Therapy for Cancer -- Personalized Management of Neurological Disorders -- Personalized Therapy of Cardiovascular Diseases -- Personalized Management of Miscellaneous Disorders -- Personalized Preventive Medicine -- Organization of Personalized Medicine -- Ethical and Regulatory Aspects of Personalized Medicine -- Economics of Personalized Medicine -- Future of Personalized Medicine.
- 2014 Springer Protocolsedited by Daniel Lafontaine and Audrey Dubé, Department of Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.Identification of regulatory RNA in bacterial genomes by genome-scale mapping of transcription start sites -- Screening inhibitory potential of anti-HIV RT RNA aptamers -- Design and evaluation of clinically relevant SOFA-HDV ribozymes targeting HIV RNA -- Directing RNase P-mediated cleavage of target mRNAs by engineered external guide sequences in cultured cells -- Design and analysis of hammerhead ribozyme activity against an artificial gene target -- Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells -- Use of tumor-targeting trans-splicing ribozyme for cancer treatment -- Characterization of hairpin ribozyme reactions -- Finding instances of riboswitches and ribozymes by homology search of structured RNA with infernal -- Structure-based virtual screening for the identification of RNA- binding ligands -- Probing riboswitch binding sites with molecular docking, focused libraries, and in-line probing assays -- Discovery of small molecule modifiers of micrornas for the treatment of HCV infection -- Bacterial flavin mononucleotide riboswitches as targets for flavin analogs -- Construction and application of riboswitch-based sensors that detect metabolites within bacterial cells -- Screening assays to identify artificial glmS ribozyme activators -- Analysis of riboswitch structure and ligand binding using small-angle X-ray scattering (SAXS) -- Use of SHAPE to select 2AP substitution sites for RNA-ligand interactions and dynamics studies -- Cell internalization SELEX: In vitro selection for molecules that internalize into cells -- DNA electronic switches based on analyte-responsive aptamers.
- 2012 SpringerIngo K. Mellinghoff, Charles L. Sawyers, editors.Setting up a Kinase Discovery and Development Project / Gideon Bollag -- Drug Efficacy Testing in Mice / William Y. Kim, Norman E. Sharpless -- Gastrointestinal Stromal Tumors / Cristina Antonescu -- EGFR Mutant Lung Cancer / Yixuan Gong, William Pao -- Targeting Oncogenic BRAF in Human Cancer / Christine A. Pratilas, Feng Xing, David B. Solit -- Beyond BRAF in Melanoma / Adil Daud, Boris C. Bastian -- JAK-Mutant Myeloproliferative Neoplasms / Ross L. Levine -- Will Kinase Inhibitors Make it as Glioblastoma Drugs? / Ingo K. Mellinghoff, Nikolaus Schultz, Paul S. Mischel -- Predictive Genomic Biomarkers / Rakesh Kumar, Rafael G. Amado -- Epigenetic Biomarkers / Timothy A. Chan, Stephen B. Baylin -- Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer / Robert L. Cohen.Also available: Print – 2012
- 2012 Springer Protocolsedited by Vladimir Voynov, Justin A. Caravella.Therapeutic proteins / Dimiter S. Dimitrov -- Synthetic antibody libraries / Bryce Nelson and Sachdev S. Sidhu -- Construction of "phylomer" peptide libraries as a rich source of potent inhibitors of protein/protein interactions / Nadia Milech and Paul Watt -- Ribosome display and screening for protein therapeutics / Damjana Kastelic and Mingyue He -- Yeast display of engineered antibody domains / Qi Zhao, Zhongyu Zhu, and Dimiter S. Dimitrov -- Expression, purification, and characterization of engineered antibody CH2 and VH domains / Rui Gong, Weizao Chen, and Dimiter S. Dimitrov -- Engineering of affibody molecules for therapy and diagnostics / Joachim Feldwisch and Vladimir Tolmachev -- Protein design for diversity of sequences and conformations using dead-end elimination / Karl J.M. Hanf -- Design and generation of DVD-Ig(TM) molecules for dual-specific targeting / Enrico DiGiammarino, Tariq Ghayur, and Junjian Liu -- Engineering and expression of bibody and tribody constructs in mammalian cells and in the yeast Pichia pastoris / Steve Schoonooghe -- Use of E. coli for the production of a single protein / Lili Mao and Masayori Inouye -- Folding engineering strategies for efficient membrane protein production in E. coli / Brent L. Nannenga and François Baneyx -- Transient expression technologies : past, present, and future / Sabine Geisse and Bernd Voedisch -- Stable transfection pools for large quantity of protein production / Jianxin Ye -- Mammalian stable expression of biotherapeutics / Thomas Jostock and Hans-Peter Knopf -- Transgenic expression of therapeutic proteins in Arabidopsis thaliana seed / Cory L. Nykiforuk and Joseph G. Boothe -- Methods for chromatographic removal of endotoxin / Adam J. Lowe, Cameron L. Bardliving, and Carl A. Batt -- Effectiveness of various processing steps for viral clearance of therapeutic proteins : database analyses of commonly used steps / Dana Cipriano, Michael Burnham, and Joseph V. Hughes -- High-throughput quantitative N-glycan analysis of glycoproteins / Margaret Doherty [and others] -- High-throughput multimodal strong anion exchange purification and N-glycan characterization of endogenous glycoprotein expressed in glycoengineered Pichia pastoris / Sujatha Gomathinayagam [and others] -- Databases and tools in glycobiology / Natalia V. Artemenko [and others] -- Characterization of PEGylated biopharmaceutical products by LC/MS and LC/MS/MS / Lihua Huang and P. Clayton Gough -- Identification of asp isomerization in proteins by 18O labeling and tandem mass spectrometry / Jennifer Zhang and Viswanatham Katta -- Monitoring of subvisible particles in therapeutic proteins / Satish K. Singh and Maria R. Toler -- Size-exclusion chromatography with multi-angle light scattering for elucidating protein aggregation mechanisms / Erinc Sahin and Christopher J. Roberts -- Computational methods to predict therapeutic protein aggregation / Patrick M. Buck [and others] -- Coarse-grained simulations of protein aggregation / Troy Cellmer and Nicolas L. Fawzi -- Chitosan-based nanoparticles as delivery systems of therapeutic proteins / Pedro Fonte [and others] -- Challenges in the development and manufacturing of antibody-drug conjugates / Laurent Ducry.
- 2007 Springeredited by Grant Cooper.
- 2014 CRCnetBASEeditors, Lukasz Komsta, Monika Waksmundzka-Hajnos, Joseph Sherma.
- 2009 SpringerMichael E. Maragoudakis, Nikos E. Tsopanoglou, editors.
- 2013 CRCnetBASEedited by Pritam S. Sahota, James A. Popp, Jerry F. Hardisty, and Chirukandath Gopinath.Overview of drug development / James A. Popp and Jeffery A. Engelhardt -- Nonclinical safety evaluation of drugs / Thomas M. Monticello and Jeanine L. Bussiere -- Toxicokinetics and drug metabolism : relating toxicity to compound exposure and disposition / David D. Christ -- Introduction to toxicologic pathology / Judit E. Markovits ... [et al.] -- Routine and special techniques in toxicologic pathology / Daniel J. Patrick, Peter C. Mann -- Principles of clinical pathology / Robert L. Hall -- Toxicogenomics in toxicologic pathology / Mark J. Hoenerhoff and David E. Malarkey -- Spontaneous lesions in control animals used in toxicity studies / Robert C. Johnson, Robert H. Spaet, Daniel L. Potenta -- Gastrointestinal tract / Judit E. Markovits -- Liver, gall bladder, and exocrine pancreas / Russell C. Cattley, James A. Popp, Steven L. Vonderfecht -- Respiratory system / David J. Lewis and Tom P. McKevitt -- Urinary system / Kendall S. Frazier and John Curtis Seely -- Hematopoietic system / Kristin Henson, Glenn Elliott, Gregory S. Travlos -- The lymphoid system / Patrick J. Haley -- Bone, muscle, and tooth / John L. Vahle ... [et al.] -- The cardiovascular system / Calvert Louden, David Brott -- Endocrine glands / Sundeep Chandra, Mark Hoenerhoff, Richard Peterson -- Reproductive system and mammary gland / Justin D. Vidal ... [et al.] -- Skin / Zbigniew Wojcinski ... [et al.] -- Nervous system / Mark T. Butt, Robert Sills, Alys Bradley -- Special senses : eye and ear / James A. Render, Kenneth A. Schafer, Richard A. Altschuler.
- 2010 SpringerR. Manjunatha Kini, Kenneth J. Clemetso, Francis S. Markland, Mary Ann McLane, Takashi Morita, editors."Circulation of blood is vital for the survival of vertebrates, including man. Mainly, it plays an important role in carrying food nutrients and oxygen to every tissue and organ and in removing all waste products and carbon dioxide. Any imbalance in the hemostatic and cardiovascular systems can lead to death and severe debility. A number of animals have developed mechanisms to target these systems and exploit the vulnerability. In some species (for example, snakes), such mechanisms are used to immobilize and kill the victim/prey, whereas in others (for example, insects, such as leaches, mosquitoes and ticks), they are used to provide a continuous supply of blood. These mechanisms include, but are not limited to, procoagulant and anticoagulant actions that affect the coagulation cascade and platelet aggregation, as well as altering vasodilatory responses. In all these various animals, these mechanisms have evolved to perfection over millions of years to support their survival. In last 3-4 decades, due to the efforts of scientists from various backgrounds including biology, protein chemistry, molecular biology, pharmacology, hematology, and structural biology, significant progress in understanding the structure-function relationships, as well as the mechanism of action have been made in a number of exogenous factors that affect blood coagulation, platelet aggregation and vasodilation from various animals. These exogenous factors have contributed significantly to the development of research tools as well as providing new therapeutic agents."
- 2011 CRCnetBASEAjay K. Banga."Skin, once thought to be an impenetrable barrier, is an extremely active organ capable of interacting with its environment. Advancements in science combined with the need for diverse drug delivery modalities have introduced a variety of transdermal and intradermal products for existing drugs at a fraction of the cost of new drug development. Commercialization of transdermal drug delivery requires technology from many disciplines beyond pharmaceutical sciences, such as polymer chemistry, adhesion sciences, mass transport, web film coating, printing, and medical technology. A comprehensive discussion of these technologies and practices, Transdermal and Intradermal Delivery of Therapeutic Agents: Application of Physical Technologies, covers: Commercial development of devices and products based on transdermal physical enhancement technologies, Selecting optimal enhancement technology for a specific drug molecule using case studies that cover physicochemical properties as well as practical commercial considerations related to cost, unmet clinical needs, marketing, or intellectual property protection, Technologies such as microneedles, iontophoresis, electroporation, and sonophoresis with examples for delivery of small molecules, cosmeceuticals, proteins, and vaccines, Practical information on experimental procedures and challenges related to skin irritation and safety issues. Up-to-date and accessible to researchers and industry experts, this book provides a comprehensive discussion of the physical approaches and practical considerations for the laboratory and marketplace"--Provided by publisher.
- 2016 SpringerRussell Weiner, Marian Kelley, editors.Foreword -- Fit-For-Purpose Validation -- Biomarkers in Drug Discovery and Development: Pre-Analytical and Analytical Considerations -- Biomarker Discovery -- Application of Quantitative Biomeasures in Early Drug Discovery -- Biomarkers in discovery and preclinical phase during drug development -- Incorporating clinical biomarkers into clinical trials -- Perspectives on Tissue Biobanking for Personalized Medicine -- The role of commercial biomarker assay kits in preclinical and clinical trials kits -- Quantification of protein biomarkers using liquid chromatography tandem mass spectrometry -- LC/MS methods for small Molecule biomarkers -- Cell-based Assays -- New Technologies for Cellular Analysis -- Flow cytometry methods for the Clinical Development of Immunomodulatory Biologics -- Key mass spectrometry techniques used in clinical biomarker research -- Clinical Genomic Biomarker Assay Development: Technologies and Issues -- Implementation of Immunohistochemistry assays for clinical trial sample analyses -- Strategic Approach to Outsourcing Clinical Biomarker Assays through CRO Relationships -- In situ hybridization (ISH) in Clinical Biomarker Development. .
- Translational research methods for diabetes, obesity and cardiometabolic drug development : a focus on early phase clinical studies2015 SpringerAndrew J. Krentz, Lutz Heinemann, Marcu Hompesch, editors.This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development. Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
- 2013 SpringerYuichi Sugiyama, Bente Steffansen, editors.Transporters in Drug Development is a corner stone in a high profile book series on advances in pharmaceutical sciences initiated by AAPS, Springer and Professor Daan Crommelin as series Editor. Transporters in Drug Development: Discovery, Optimization, Clinical Study and Regulation list chapters written by leading researchers in the transporter field from academia, pharmaceutical industry and medicines agencies. The book encompasses examples and advises on how membrane transporters can be dealt with in academic industrial drug discovery and pharmaceutical development as well as from a regulatory perspective. Methods and examples of in vitro characterization of single transporters in intestine, liver and kidney are described as well as characterization of substrate overlap between various transporters. Furthermore, probes and biomarkers are suggested for studies of the transporters impact on the pharmacokinetics of drug substrates/candidates interacting on transporters. The challenges of translating in vitro observed interaction of transporters into in vivo relevance are discussed as well as the perspectives of applying targeted proteomics and mechanistic modelling in this process.
- v.1-2=, 2012 Springer Protocols2nd ed., 2014 Springer Protocolsedited by Arpad Szallasi, Tamás Bíró.V. 1. Introduction to TRPs : a quest for novel drug targets / Bernd Nilius -- TRP-mediated cytoskeletal reorganization : implications for disease and drug development / Chandan Goswami -- TRPA1 in drug discovery / Jun Chen, Steve McGaraughty, and Philip R. Kym -- Canonical transient receptor potential channel expression, regulation, and function in vascular and airway diseases / Brij B. Singh, Christina M. Pabelick, and Y.S. Prakash -- TRPM2 function and potential as a drug target / Barbara A. Miller -- Ca2+-activated monovalent cation-selective channels TRPM4 and TRPM5 / Barbara Colsoul ... [et al.] -- Emerging role of TRPM7 in the regulation of magnesium homeostasis / Vladimir Chubanov ... [et al.] -- TRPM8 channels as potential therapeutic targets for pain, analgesia, and thermoregulation / David D. McKemy -- TRPML channels in function, disease, and prospective therapies / David A. Zeevi -- TRPP signaling module : TRPP2/polycystin-1 and TRPP2/PKD1L1 / Alexis Hofherr -- TRPV1 as a polymodal sensor : potential to discover TRPV1 antagonists selective for specific activating modalities / Olivier Radresa ... [et al.] -- Nociceptive and nonnociceptive roles of TRPV3 and its "druggability" / Sungjae Yoo and Sun Wook Hwang -- TRPV4 and drug discovery / Fabien Vincent and Matthew A.J. Duncton -- TRP expression and function in the lung airways / Alexander Dietrich and Thomas Gudermann -- Hypoxia-dependent TRP channel function in pulmonary arterial smooth muscle cells / Beate Fuchs ... [et al.] -- Endotoxin-induced airway inflammation and asthma models / Zsuzsanna Helyes and Zsofia Hajna -- Enhanced cough, animal models / Raffaele Gatti ... [et al.] -- Capsaicin inhalation test in man / Eva Millqvist -- TRP channels in the genitourinary tract / Ana Charrua and Francisco Cruz -- Animal models of cystitis / Celia D. Cruz and Antonio Avelino -- Overactive bladder models / Roberto Soler ... [et al.] V. 2. TRPs to cardiovascular disease / José C. González-Cobos, Xuexin Zhang, Rajender K. Motiani, Kelly E. Harmon, and Mohamed Trebak -- Anemic zebrafish models of cardiomyopathy / Xiaojing Sun and Xiaolei Xu -- Methods to study the effects of TRP channel drugs on vascular endothelial cell function / Yan Ma, Yung-Wui Tjong, and Xiaoqiang Yao -- Atherosclerosis models with cell-mediated calcification / Beili Zhu -- Models of hypertension and blood pressure recording / Luciana Aparecida Campos and Ovidiu Constantin Baltatu -- Balloon injury in rats as a model for studying TRP channel contribution to vascular smooth muscle remodeling / Wei Zhang and Mohamed Trebak -- TRP channels in the brain / Antonio Reboreda -- Investigation of the possible role of TRP channels in schizophrenia / Loris A. Chahl -- Investigating diseases of dopaminergic neurons and melanocytes using zebrafish / Amanda Decker and Robert Cornell -- A practical guide to evaluating anxiety-related behavior in rodents / Caitlin J. Riebe and Carsten T. Wotjak -- Rodent models of conditioned fear: behavioral measures of fear and memory / Jennifer L. McGuire, Jennifer L. Coyner, and Luke R. Johnson -- Chick anxiety-depression screening model / Stephen W. White and Kenneth J. Sufka -- A clinically relevant thromboembolic stroke model in the aged rat / Ryan C. Turner, Alisa S. Elliott, Jason D. Huber, and Charles L. Rosen -- Use of cell-stretch system to examine the characteristics of mechanosensor channels: axonal growth/neuroregeneration studies / Koji Shibasaki -- Methods in neuronal growth cone biology / Robert J. Gasperini and Lisa Foa -- Transient receptor potential channels and pruritus / Heike Benecke, Janine Wäring, Tobias Lotts, and Sonja Ständer -- Skin sensitivity studies / Laurent Misery -- Hair follicle culture / Michael P. Philpott -- Animal models for type 1 diabetes / Anish Suri and Matteo Levisetti -- Type 2 diabetes models / Dorte X. Gram -- Using diet to induce metabolic disease in rodents / Angela M. Gajda, Michael A. Pellizzon, and Matthew R. Ricci -- Rodent models to evaluate anti-obesity drugs / Sharon C. Cheetham and Helen C. Jackson -- Experimental colitis models / Patrick A. Hughes, Stuart M. Brierley, Joel Castro, Andrea M. Harrington, and L. Ashley Blackshaw -- Tumor xenograft models to study the role of TRP channels in Tumorigenesis / V'yacheslav Lehen'kyi, Sergii Khalimonchyk, Albin Pourtier, Maylis Raphaël, and Natalia Prevarskaya -- Methods to study thermonociception in rodents / Kata Bölcskei -- Methods for the assessment of heat perception in humans / Michael F. Crutchlow and Joel D. Greenspan -- Collagen antibody-induced arthritis: a disease-relevant model for studies of persistent joint pain / Katalin Sandor, Kutty Selva Nandakumar, Rikard Holmdahl, and Camilla I. Svensson -- Animal models of muscular dystrophy / Yuko Iwata and Shigeo Wakabayashi -- Concluding remarks.
- 2008 SpringerDieter Marmé, Norbert Fusenig, (editors).
- 2014 Springeredited by Steven Kanner.
- 2012 SpringerGraham Molineux, Tara Arvedson, MaryAnn Foote, editors.
- 2006 HighWireedited by Jean-Pierre Bassand.
- 2010 CRCnetBASEedited by Walter A. Korfmacher.Strategies and techniques for bioanalytical assays as part of new drug discovery / Walter A. Korfmacher -- The drug discovery process: from molecules to drugs / Mike S. Lee, Steven E. Klohr -- PK principles and PK/PD applications / Hong Mei, Richard A. Morrison -- Mass spectrometry for in vitro ADME screening / Inhou Chu -- Metabolite identification strategies and procedures / Ragu Ramanathan, S. Nilgün Çömezoǧlu, W. Griffith Humphreys -- Reactive metabolite screening and covalent-binding assays / Gérard Hopfgartner -- Fast metabolite screening in a discovery setting / Xiaoying Xu -- Fast chromatography with UPLC and other techniques / Sam Wainhaus -- Supercritical fluid chromatography-mass spectrometry / Yunsheng Hsieh -- Biomarkers of efficacy and toxicity: discovery and assay / Joanna R. Pols -- Imaging mass spectrometry for small molecules / Fangbiao Li -- MALDI IMS for proteins and biomarkers / Michelle L. Reyzer, Richard M. Caprioli -- Ambient ionization methods and their early applications in ADME studies / Jing-Tao Wu -- Pharmaceutical applications of accelerator mass spectrometry / Lan Gao, Swapan Chowdhury.
- 2015 McGraw-Hill eBook LibraryTerriann Crisp, PhD, Crisp Enterprises: Pharmacology Instruction and Consultation, LLC, Ankeny, Iowa.Section 1. Autonomic Pharmacology -- Section 2. Cardiovascular Pharmacology -- Section 3. Neuropharmacology -- Section 4. Antibiotics -- Section 5. Pharmacokinetic and Pharmacodynamic Principles.
- 2011[author, Lionel P. Raymon ; coauthors, Craig Davis, Steven R. Harris ; contributors, Maris Victor Nora, Anthony Trevor].Section I. General principles -- Section II. Automonic pharmacology -- Section III. Cardiac and renal pharmacology -- Section IV. CNS pharmacology -- Section V. Antimicrobial agents -- Section VI. Drugs for inflammatory and related disorders -- Section VII. Drugs used in blood disorders -- Section VIII. Endocrine pharmacology -- Section IX. Anticancer drugs -- Section X. Immunopharmacology -- Section XI. Toxicology -- Index.
- 2006 SpringerII Springereditors, Salvador Moncada and Annie Higgs.
- 2014 SpringerPeter C. Ruben, editor.A number of techniques to study ion channels have been developed since the electrical basis of excitability was first discovered. Ion channel biophysicists have at their disposal a rich and ever-growing array of instruments and reagents to explore the biophysical and structural basis of sodium channel behavior. Armed with these tools, researchers have made increasingly dramatic discoveries about sodium channels, culminating most recently in crystal structures of voltage-gated sodium channels from bacteria. These structures, along with those from other channels, give unprecedented insight into the structural basis of sodium channel function. This volume of the Handbook of Experimental Pharmacology will explore sodium channels from the perspectives of their biophysical behavior, their structure, the drugs and toxins with which they are known to interact, acquired and inherited diseases that affect sodium channels and the techniques with which their biophysical and structural properties are studied.
- 2005 PsychiatryOnlineedited by Robert E. Hales, Stuart C. Yudofsky, Robert H. Chew.
- 2004 WHOPart I. WHO Guidelines on safety monitoring of herbal medicines in pharmacovigilance systems -- 1. General introduction -- 1.1. Introduction -- 1.2. Background -- 1.3. Objectives -- 1.4. Glossary -- 2. Pharmacovigilance and the WHO International Drug Monitoring Programme -- 2.1. What is pharmacovigilance? -- 2.2. How does pharmacovigilance operate? -- 3. Challenges in monitoring the safety of herbal medicines -- 3.1. Regulation, quality assurance and control -- 3.2. Appropriate use -- 4. Safety monitoring of herbal medicines -- 4.1. Sources of reports -- 4.2. Herbal products targeted for safety monitoring -- 4.3. Reporting of suspected adverse reactions -- 4.4. Assessment of case reports -- 4.5. Data management -- 5. Communication -- 5.1. General -- 5.2. Risk communication -- 6. References -- 7. Selected bibliography -- Safety monitoring and pharmacovigilance -- Regulation of herbal medicines/traditional medicines -- Quality assurance/control of herbal medicines -- Rational use of herbal medicines -- Annex 1. List of participants in the WHO Consultation on Safety Monitoring of Herbal Medicines, Vancouver, Canada, 1-3 February 2004 -- Annex 2. The Erice Declaration on Communicating Drug Safety Information, 1997 -- Annex 3. Privacy and the confidentiality of personal health data -- Annex 4. Spontaneous reports from persons other than health-care professionals -- Annex 5. Model reporting form -- Annex 6. Proposed database management and classification for coding herbal products (the Uppsala Monitoring Centre, Uppsala, Sweden) -- Part II. Safety monitoring of medicinal products: Guidelines for setting up and running a pharmacovigilance centre (The Uppsala Moniroring Centre, Uppsala, Sweden, 2000.
- 5-HT2C receptors in the pathophysiology of CNS disease — Developing drug products in an aging society : from concept to prescribing (130)
- Development of antibody-based therapeutics : translational considerations — Leading pharmaceutical innovation : trends and drivers for growth in the pharmaceutical industry. 2nd ed. (130)
- Lippincott's Illustrated reviews. Pharmacology. 4th ed. — Pharmacology-- PreTest self-assessment and review. 13th ed. (130)
- Pharmacology : PreTest self-assessment and review. 12th ed. — WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems (128)
- Harrison's Principles of Internal Medicine
- AAP Red Book Online
- Robbins & Cotran Pathologic Basis of Disease
- Sabiston Textbook of Surgery
- Nelson's Textbook of Pediatrics
- Surgical Exposures in Orthopaedics
- Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases
- Red Book Online
- ICU Book
- Primary Care Medicine
- Campbell-Walsh Urology
Access restricted to Stanford community
Shortcut to Licensed Content
TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.
Bookmark on Other Websites
- TO INSTALL, RIGHT CLICK this button.
- Select "Add to Favorites" (click “Continue” if you see a security alert)
- From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
- Once installed it will look like this
- Click "Bookmark on Lane" to bookmark any webpage
- Your saved bookmark will appear on this page
Can't find it?
Look if we have it in print
- Springer Protocols
- Lange Series
- National Academy Press
- NCBI Bookshelf
- Thieme Atlases
A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.
Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed Plus is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available.Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.
Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.
Includes cited reference searching, citation maps, and an analyze tool.
Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.
Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.
Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.
In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.
A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.
Over 10,000 notes outline the status of specific infections within each country.
Provides online, full-text access to Springer's journal titles as well as journals from other publishers.
Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.